Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study
Mia Rodziewicz, Sarah Dyball, Mark Lunt, Stephen McDonald, Emily Sutton, Ben Parker, Ian N Bruce, Rikki Abernethy, Yasmeen Ahmad, Mohamed Akil, Sarah Bartram, Mike Batley, Anurag Bharadwaj, Ian N Bruce, Francesco Carlucci, Antoni Chan, Bhaskar Dasgupta, David D'Cruz, Denise De Lord, Bernard DykeChristopher Edwards, Nicola Erb, Adrian Farrell, Mary Gayed, Nagui Gendi, Luke Gompels, Caroline Gordon, Patrick Gordon, Bridget Griffiths, Nicola Gullick, Harsha Gunwardena, Richard Haigh, Shahir Hamdulay, Sahena Haque, David Hutchinson, David Isenberg, David Jayne, Rachel Jeffery, Deepti Kapur, Arvind Kaul, Jon King, Sally Knights, Ellie Korendowych, Peter Lanyon, Madhu Mahindrakar, Jonathan Marks, Liza McCann, Zoe McLaren, Rapti Mediwake, Ajit Menon, Devesh Mewar
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study'. Together they form a unique fingerprint.